NEW: [Thread] 1. #JnJ 2day announced (via a press release: bit.ly/3AFFCu0): 1. JnJ's #COVID19 jab = more effective when given as a double shot, 56 days - 6 mnths apart (vs. just 1 shot) 2. The efficacy of 1 shot doesn't wane, but a booster shot makes it more effective.
2. When a 2nd #JnJ shot is given 56 days after the 1st one, the 2-dose combo provides:
* 100% protection @ severe #COVID19 14 days after the 2nd shot
* 75% protection @ symptomatic (moderate to severe/critical) COVID19 in the countries where the jab was tested
3. When a 2nd/booster shot of the #JnJ#COVID19 jab was given 56 days after the first shot, trial participants' antibody levels rose to 4-6x times higher than after just one shot.
4. But when a 2nd/booster shot was given 6 months after the 1st shot, antibody levels increased even more than when it was given 56 days apart:
* 56 days interval: 4-6-fold increase in antibodies
* 6 months interval: 12-fold increase in antibodies (4 weeks after the 2nd shot)
A JnJ preprint study, using real-life data (claims from an insurance company) to analyse the efficacy of 1 dose shows:
* 81% effectiveness @ #COVID hospitalisations
* 79% effectiveness @ #COVID19 infection
6. What does this all mean? Statnews says:
"The data appears to set the stage for a discussion over whether the #JnJ vaccine should be thought of as a 2-dose regimen, with the doses given 6 months apart."
7. But for #JnJ to be considered as 2 doses, A LOT more needs to happen:
* Regulators such as the FDA need to convene open meetings
* Much more detailed data will need to be made public/published (and peer reviewed)
8. So what now? #JnJ says it has/will submit data to:
* The US Food and Drug Administration (FDA) and other regulators
* The WHO and National Immunization Technical Advisory Groups
9. What will happen in SA? We will continue to use one dose of #JnJ until data has been submitted to Sahpra (our regulator) and reviewed by the body. If Sahpra approves the data, the health dpt can then decide if two doses are necessary or not.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
🧵1. BREAKING: The peer-reviewed results of the study of a 6-monthly jab, #lenacapavir, in which not a single of the 2134 women between 16-25 years who received the jab contracted #HIV, were released at #Aids2024.
2. Women often find it hard to adhere to daily #oralPrEP. In the Purpose 1 trial, 91.5% of women returned on time for their next #lenacapavir jab at 26 weeks and 92.8% at week 52.
3. Only 4 women out of 2134 (0.2%) who received #lenacapavir dropped out of the trial because of injection-site reactions.
[Thread] 12 things to know about the the proportion of pregnant women infected with #HIV from SA’s latest antenatal HIV survey. The survey is conducted by the @nicd_sa.
(Analysis of our 95-95-95 goals in my next thread later in Jan).
1/12
2. What is the antenatal #HIV survey?
1. It measures the % of HIV+ pregnant women between the ages of 15 + 49. 2. Only women using state pregnancy clinics take part. 3. The survey has been conducted each year between 1990-2015, then in 2017, 2019 +2022.
3. How many pregnant women between 15-49’s blood was tested for #HIV? 37 828 out of 40 542 collected samples.
- 37 7171 = Black African women
- 37 541 didn’t live with the dad of their child
- 35,635 of dads were 5 years+ older than moms (this makes them more likely to get HIV)
JUST IN [Thread]:
1.@healthza's Lesley Broomberg:
An extra #COVID19 booster jab for people of 18+ in SA will become available towards the end of JANUARY
- People of 50+ qualify for a 5th dose
- People of 18+ qualify for a 4th dose
2. Lesley Broomberg: Can you mix and match with additional boosters? Yes. You can choose whether you want a #JnJ or #Pfizer booster.
3. Lesley Broomberg:
Will teens of 12-17 qualify for boosters? Not at this stage. Why not? The #VMAC = not recommended booster doses for 12-17, based on an understanding that the protection provided by 2 #Pfizer doses = adequate, as 12-17 = @ low risk of severe #COVID19 illness
[Thread] #JoePhaahla:
- Genomic surveillance Network reported the detection of the new subvariant XBB.1.5 in SA of a sample of a patient tested on 22 Dec
- Details of the patient = not known, it was a random sample taken for testing
- XBB.1.5 = also common in US
2. XBB.1.5 = common in US
#JoePhaahla:
- 97%+ of #COVID19 cases worldwide = still #Omicron
- XBB.1.5 cases = no major change in hospitalisations or deaths
- Immunity of SAs (vax and natural immunity) = still strong, so that is why we haven't seen much change in terms of hospital admissions/deaths
Which APIs will Aspen use?
India's Serum Institute's
2. Why is it NB that an African company makes these jabs?
#Africa imports almost all its jabs. #COVID19 showed us this results in Africa being last in line to get vaccines during pandemics. The grant to Aspen is 1 of the 1st steps to change that.
3. What's the goal?
By 2040, the African Union wants #Africa to make 60% of the jabs the continent uses.
Why?
So that Africa is better equipped 2 respond 2 outbreaks (by developing the ability to make jabs + have technology in place to also make new jabs during pandemics).
🧵1. BREAKING: @SAHPRA1 has confirmed the registration of the #HIV prevention jab, #CABLA in South Africa. On Thursday, #ViiVHealthcare issued their statement.
2. Who can use the jab? @SAHPRA1 didn't specify restrictions for use in their statement, only that it is "a highly effective option for people at substantial risk of #HIV infection."
3. How does the jab work? It uses an #ARV called cabotegravir that prevents #HIV from replicating and entering someone’s cells. It’s taken every two months. Read my latest story for more. bit.ly/3ER7ejq